NAD+ Precursors in Research: NR, NMN, and the Experimental-Design Problem

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every living cell, central to redox reactions and a required substrate for enzymes such as sirtuins, PARPs and CD38. Because tissue NAD+ levels are reported to decline with age in several models, a large literature has formed around raising it, either by giving NAD+ itself or by giving precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The experiments are harder to design than they look. This article covers how NAD+ is made and consumed, how the main precursors compare, and the specific pitfalls that make NAD+ results easy to misread. For the clinical-trial summary, see our NAD+ research overview.

Three Routes to NAD+

  • De novo pathway: from the amino acid tryptophan via the kynurenine pathway.
  • Preiss-Handler pathway: from nicotinic acid (niacin).
  • Salvage pathway: recycling nicotinamide, the by-product of NAD+-consuming reactions, back to NAD+ through nicotinamide phosphoribosyltransferase (NAMPT) and NMN. This is the dominant route in most mammalian tissues. NR enters through phosphorylation to NMN by nicotinamide riboside kinases.

NAD+ is also consumed continuously. A comprehensive review by Covarrubias, Perrone, Grozio and Verdin describes the main sinks: sirtuin deacylases, PARP enzymes in DNA repair, and the ecto-enzyme CD38 (Nat Rev Mol Cell Biol 2021;22:119-141). Camacho-Pereira and colleagues reported that CD38 expression rises with age in mouse tissues and that this correlated with falling NAD+ levels (Cell Metab 2016;23:1127-1139), making CD38 a prominent mechanistic hypothesis for the age-related decline.

NAD+ Itself Versus Precursors

Intact NAD+ is a large, charged molecule that crosses cell membranes poorly. Extracellular NAD+ is broken down by CD38 and related ecto-enzymes into smaller fragments that cells can take up and rebuild. In cell-culture work, this means that adding NAD+ to the medium may raise intracellular NAD+ through breakdown-and-resynthesis and not through direct transport, a distinction that matters for interpreting results. Precursors enter the salvage pathway more directly.

NR and NMN: What the Research Reports

  • NR bioavailability. Trammell and colleagues reported that oral NR was bioavailable in mice and humans and raised NAD+ metabolites in blood (Nat Commun 2016;7:12948).
  • NR in healthy adults. Martens and colleagues reported that chronic NR supplementation was well tolerated and increased blood NAD+ in healthy middle-aged and older adults (Nat Commun 2018;9:1286).
  • NR and metabolic outcomes. In a randomized trial in obese men, Dollerup and colleagues reported that NR raised NAD+ metabolites but did not improve insulin sensitivity (Am J Clin Nutr 2018;108:343-353).
  • NMN and insulin sensitivity. Yoshino and colleagues reported that NMN increased muscle insulin sensitivity in prediabetic women (Science 2021;372:1224-1229), while their earlier mouse work showed improvements in diet- and age-induced diabetes models (Cell Metab 2011;14:528-536).
  • NMN transport. A proposed NMN-specific transporter, Slc12a8, was reported in 2019 (Grozio et al., Nat Metab 2019;1:47-57); whether NMN is taken up intact or after conversion to NR remains debated.

The pattern across these studies: precursors reliably raise measured NAD+ metabolites, while functional outcomes are mixed and population-dependent. Reviews such as Yoshino, Baur and Imai (Cell Metab 2018;27:513-528) emphasize that raising NAD+ and obtaining a benefit are separate claims.

The Experimental-Design Problem

  1. Compartmentation. NAD+ pools differ across nuclear, cytosolic and mitochondrial compartments. A whole-cell or whole-blood NAD+ number can hide changes in a single compartment, and blood NAD+ may not reflect tissue NAD+.
  2. Measurement method. Enzymatic cycling assays, HPLC and LC-MS/MS can give different absolute values. LC-MS/MS with isotope-labeled internal standards is the more specific method for NAD+ and related metabolites.
  3. Extraction chemistry. NAD+ is stable in acid but degrades in alkaline conditions, while NADH is the reverse; extraction buffers that favor one oxidation state can destroy the other, and sample handling must be fast and cold.
  4. Ratio versus level. The NAD+/NADH ratio and absolute levels answer different questions; report which is used.
  5. Timing. Precursor-induced rises may be transient, so single time points can mislead.
  6. Controls. A vehicle-matched control, a nicotinamide-only arm (to separate NAD+ effects from nicotinamide's own effect on sirtuins and PARPs), and where possible an NAMPT inhibitor (FK866) or CD38 inhibitor arm help test pathway specificity.
  7. Reagent stability. NAD+ solutions should be prepared fresh, buffered to a mildly acidic or neutral pH, kept cold, and verified by an identity and purity analysis as with any reagent.

Open Questions

  • Which tissue pools matter for which outcomes?
  • Do precursor-induced increases in blood NAD+ translate to muscle, brain or liver?
  • What is the role of CD38 inhibition versus precursor supply?
  • Why do rodent benefits translate inconsistently in human trials?

Sources

  • Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021;22:119-141.
  • Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018;27:513-528.
  • Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016;7:12948. doi:10.1038/ncomms12948
  • Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018;9:1286.
  • Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018;108:343-353.
  • Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372:1224-1229.
  • Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab 2016;23:1127-1139.
  • Grozio A, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 2019;1:47-57.

For research use only. Not for human or veterinary consumption. This article is educational and describes published literature; it makes no claims about the use of any product.